Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma: Myth or Reality?

BACKGROUND: Due to the relative rarity of small bowel adenocarcinoma (SBA), prospective trials, helping to guide therapeutic decisions, are lacking and the optimal therapy for advanced SBA is unknown. The role of targeted agents, such as anti–epidermal growth factor receptor (EGFR) and anti–vascular...

Descripción completa

Detalles Bibliográficos
Autores principales: Dell’Aquila, Emanuela, Zeppola, Tea, Stellato, Marco, Pantano, Francesco, Scartozzi, Mario, Madaudo, Cristina, Pietrantonio, Filippo, Cremolini, Chiara, Aprile, Giuseppe, Vincenzi, Bruno, Moretto, Roberto, Puzzoni, Marco, Garattini, Silvio Ken, Lobefaro, Riccardo, Tonini, Giuseppe, Santini, Daniele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7412900/
https://www.ncbi.nlm.nih.gov/pubmed/32821190
http://dx.doi.org/10.1177/1179554920946693

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7412900/
https://www.ncbi.nlm.nih.gov/pubmed/32821190
http://dx.doi.org/10.1177/1179554920946693

Ejemplares similares